Comparative Pharmacology
Head-to-head clinical analysis: SOMOPHYLLIN DF versus TORNALATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SOMOPHYLLIN DF versus TORNALATE.
SOMOPHYLLIN-DF vs TORNALATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Theophylline relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing intracellular cAMP, and blocking adenosine receptors.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.
Oral: 300-600 mg every 12 hours; extended-release tablets. Titrate to serum theophylline concentration of 5-15 mcg/mL.
2 puffs (340 mcg) inhaled via oral inhalation 4 times daily; maximum 12 puffs/day.
None Documented
None Documented
Terminal elimination half-life: 3–12 hours in healthy adults; prolonged in hepatic impairment (up to 30 hours), congestive heart failure, and in neonates; also prolonged in elderly and patients with fever or viral illness. Half-life is shorter in smokers (4–5 hours).
Terminal elimination half-life is approximately 9-12 hours in healthy adults. May be prolonged in elderly or those with hepatic impairment, necessitating dose adjustment.
Renal excretion of unchanged drug: approximately 10%; hepatic metabolism accounts for >90% of elimination; metabolites are excreted renally. Less than 5% eliminated in feces.
Primarily renal excretion of unchanged drug and metabolites; <10% fecal. Approximately 60-70% of a dose is recovered in urine as unchanged drug and glucuronide conjugates within 24 hours.
Category C
Category C
Bronchodilator
Bronchodilator